Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1803 plus anti-CD38 mAb in RRMM
NCT07090954Phase 2Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in multiple myeloma (MM), sponsored by Zhixiang Jintai. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07090954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090954.